Follicular and luteal phases

What it is

The follicular and luteal phases are the two principal divisions of the menstrual cycle — the body's monthly hormonal sequence that prepares the ovaries and uterus for potential pregnancy. In a median 28-day cycle (most cycles fall between 24 and 38 days, per FIGO criteria), the follicular phase occupies roughly days 1 through 14 and the luteal phase occupies roughly days 15 through 28. A key clinical fact: the luteal phase is nearly fixed at 14 days across individuals, meaning virtually all cycle-length variation comes from a longer or shorter follicular phase, which can range from 10 to 16 days. Menstrual cycles are most irregular at the extremes of reproductive life — around menarche (median onset age 12.4 in Canada) and perimenopause (average onset around age 51) — largely because of anovulation and inconsistent follicular development.

For Canadian patients, understanding these phases matters clinically: irregular cycles, absent ovulation, or a shortened luteal phase can affect fertility assessments ordered through LifeLabs or Dynacare, and are relevant to conditions evaluated under SOGC clinical guidelines, including polycystic ovary syndrome (PCOS), endometriosis, and premature ovarian insufficiency.

Feature	Follicular Phase	Luteal Phase
Cycle days (28-day cycle)	Days 1–14	Days 15–28
Duration variability	High (10–16 days)	Low (~14 days, fixed)
Dominant hormone	Estradiol (rising)	Progesterone (dominant)
Ovarian event	Follicle recruitment and growth	Corpus luteum formation
Endometrial state	Proliferative (thickening)	Secretory (receptive)
FSH trend	Rises early, then falls	Low
LH trend	Surges at end of phase	Low after surge

Causes and mechanism

Both phases are orchestrated by the hypothalamic-pituitary-ovarian (HPO) axis — a feedback loop involving gonadotropin-releasing hormone (GnRH) from the hypothalamus, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary, and estradiol and progesterone from the ovaries.

Follicular phase: Rising FSH at the start of the cycle recruits a cohort of ovarian follicles. One dominant follicle emerges and produces increasing amounts of estradiol, which thickens the endometrium (proliferative phase). As estradiol peaks, it triggers a positive feedback surge of LH — the LH surge — which initiates ovulation roughly 36 hours later, marking the end of the follicular phase.

Luteal phase: After ovulation, the ruptured follicle transforms into the corpus luteum, a temporary endocrine structure that secretes progesterone (and some estradiol). Progesterone shifts the endometrium into its secretory phase, making it receptive to embryo implantation. If fertilization does not occur, the corpus luteum degenerates after approximately 14 days, progesterone and estradiol fall sharply, and the endometrial lining sheds — triggering menstruation and restarting the follicular phase.

Symptoms and diagnosis

Most people with regular cycles experience predictable phase-linked symptoms. During the follicular phase, rising estradiol is generally associated with higher energy, improved mood, and increased libido. Around ovulation, some notice mid-cycle pelvic pain (mittelschmerz) or a change in cervical mucus to a clear, stretchy consistency.

During the luteal phase, rising and then falling progesterone can cause bloating, breast tenderness, sleep disruption, and mood changes. When these symptoms are severe enough to impair daily function, the pattern may meet criteria for premenstrual dysphoric disorder (PMDD), which affects approximately 3–8% of people with cycles.

Clinicians assess cycle phase through:

• Serum hormone levels (FSH, LH, estradiol, progesterone) — available through LifeLabs and Dynacare across Canadian provinces
• Basal body temperature (BBT) charting — a rise of ~0.2–0.5°C signals post-ovulatory progesterone rise
• Urinary LH testing (ovulation predictor kits) — detects the LH surge 24–36 hours before ovulation
• Transvaginal ultrasound — tracks follicle size and confirms ovulation

A mid-luteal progesterone level (typically drawn on day 21 of a 28-day cycle, or 7 days before expected menses) above 16–32 nmol/L is generally used in Canadian practice to confirm ovulation, though reference ranges vary by laboratory.

Treatment options

Treatment targets the specific phase-related dysfunction rather than the phases themselves.

Anovulation / irregular follicular phase: Ovulation induction with letrozole or clomiphene citrate is first-line per SOGC guidance for people with PCOS or unexplained anovulatory infertility. Lifestyle interventions (weight management, exercise) can restore ovulatory cycles in some cases.

Luteal phase deficiency: Progesterone supplementation (oral micronized progesterone or vaginal progesterone) is used in assisted reproduction and sometimes in recurrent pregnancy loss, though evidence for its benefit in natural cycles remains debated.

PMDD and luteal-phase mood symptoms: Selective serotonin reuptake inhibitors (SSRIs) taken continuously or only during the luteal phase are first-line. Combined hormonal contraceptives — particularly those containing drospirenone — are also used. In Canada, these are available by prescription and covered under most provincial drug benefit plans for eligible patients.

Perimenopause-related cycle irregularity: As ovarian reserve declines, follicular phase length becomes increasingly unpredictable. Menopausal hormone therapy (MHT) does not restore natural cycling but can address symptoms; SOGC's 2021 menopause guidelines provide Canadian-specific prescribing context.

When to see a clinician in Canada

Seek assessment if you experience:

• Cycles consistently shorter than 24 days or longer than 38 days
• Menstrual bleeding lasting more than 8 days or blood loss that soaks through a pad or tampon hourly for several consecutive hours
• Complete absence of periods for 3 or more months (amenorrhea) outside of pregnancy
• Luteal-phase mood symptoms severe enough to affect work, relationships, or daily activities
• Difficulty conceiving after 12 months of unprotected intercourse (or 6 months if over age 35)

Family physicians, gynecologists, and reproductive endocrinologists across Canada can order the relevant hormone panels. Telehealth platforms such as Maple, Felix, and Cleo offer virtual consultations for initial cycle-related concerns, which can be a practical first step before specialist referral.

Limitations and open questions

Research is still emerging on several aspects of cycle phase physiology. The clinical significance of a "short luteal phase" in natural (non-assisted) conception cycles is not firmly established, and there is no universally agreed progesterone threshold that defines luteal phase deficiency. Studies on cycle-phase effects on exercise performance, cognitive function, and immune response have produced inconsistent results, partly because most trials have been small and used different methods to confirm cycle phase. Health Canada has not issued specific guidance on cycle-phase-based hormone testing protocols, so reference intervals for mid-luteal progesterone vary between Canadian laboratories. The interaction between hormonal contraception and the HPO axis after discontinuation — including how quickly natural phase cycling resumes — is an area of active investigation. Individuals with conditions such as thyroid dysfunction, hyperprolactinemia, or eating disorders may have phase patterns that deviate substantially from textbook descriptions, and these secondary causes should be ruled out before attributing irregularity to primary ovarian or hypothalamic factors.